Posted on September 16th, 2011 by
The experimental epilepsy drug perampanel significantly reduced the frequency of partial-onset seizures as an adjunct therapy in treatment-resistant patients…With these results, the drug's manufacturer, Eisai Inc, is submitting an application for US Food and Drug Administration (FDA) approval, presenter Jacqueline French, MD, told Medscape Medical News…"I look at the latest information as a very promising piece for this agent," said Joseph Sirven, MD, professor of neurology at the Mayo Clinic in Phoenix, Arizona, and editor-in-chief of Epilepsy.com. "The responder rate places it very much in the context of other antiepileptic drugs," he said in an interview with Medscape Medical News.
Medscape, Kate Johnson, 9/16/11
You must be logged-in to the site to post a comment.